Blepharitis

Table of Contents

  1. Overview
  2. Epidemiology
  3. Anterior vs. Posterior Blepharitis
  4. The Demodex Connection
  5. Meibomian Gland Dysfunction and Dry Eye
  6. Seborrheic Dermatitis Association
  7. Symptoms and Diagnosis
  8. First-Line Treatment: Warm Compresses and Lid Hygiene
  9. The Baby Shampoo Myth
  10. Medications: Azithromycin, Doxycycline, Topical Steroids
  11. Intense Pulsed Light (IPL) for MGD-Associated Blepharitis
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Overview

Blepharitis is chronic inflammation of the eyelid margins — the rims of the eyelids where the lashes grow. It is one of the most common eye conditions seen in primary care and ophthalmology, yet it is frequently under-diagnosed because its symptoms overlap with dry eye disease and conjunctivitis. Patients are often told they have "allergies" or "irritated eyes" for years before a correct diagnosis is made.

Blepharitis is rarely dangerous. It does not cause blindness. But it is persistent, uncomfortable, and frustrating. There is no cure — only control. The condition tends to wax and wane, with flares during stress, illness, or seasonal allergen exposure and relative quiet during stretches of diligent lid hygiene.

The key message for patients: consistent daily lid hygiene is the foundation of management, much like brushing teeth for dental health. Just as brushing eliminates the plaque and bacteria that cause gum disease, daily lid scrubs and warm compresses remove the debris, bacteria, and thickened oils that perpetuate eyelid inflammation. Patients who treat blepharitis as a "course of treatment" — doing lid hygiene for a few weeks and then stopping — almost always relapse. The routine must become permanent.

Understanding what kind of blepharitis you have matters, because treatment differs. Anterior blepharitis targets the lash base; posterior blepharitis (meibomian gland dysfunction) targets the oil-secreting glands deeper in the lid. Many people have both.

Back to Table of Contents

Epidemiology

Blepharitis is strikingly common. Studies of ophthalmic clinic populations find prevalence rates ranging from 37% to 47%, making it one of the most frequently encountered diagnoses in eye care. In primary care settings it is even more often missed, because clinicians may not have a slit lamp to examine the lid margins closely.

Prevalence increases sharply with age. Meibomian gland dysfunction — the most common form of blepharitis in older adults — is present in roughly 70% of people over 60. The meibomian glands gradually atrophy with age, producing less oil and of lower quality, much as other glandular tissues decline.

Despite the age trend, blepharitis is not exclusively a disease of older adults. Staphylococcal anterior blepharitis is relatively common in children and young adults. Children may present with recurring styes, morning crusting, and lid redness before the chronic nature becomes apparent. Demodex blepharitis, once thought to affect mainly the elderly, is now recognized at all ages in contact lens wearers and immunocompromised individuals.

Key associations include:

The condition is almost always bilateral, although it may be asymmetric. Unilateral blepharitis should prompt consideration of other diagnoses, including lid tumors (sebaceous gland carcinoma can masquerade as chronic unilateral blepharitis — a classic diagnostic trap).

Back to Table of Contents

Anterior vs. Posterior Blepharitis

Blepharitis is classified anatomically into anterior and posterior types based on which part of the lid margin is primarily affected. This distinction guides treatment and helps explain why some patients respond to antibiotics while others respond better to heat and expression.

Anterior Blepharitis

Anterior blepharitis involves the front (outer) portion of the lid margin — the skin, the lash follicles, and the accessory glands near the lash roots. Two subtypes are distinguished:

In practice the two anterior subtypes often coexist, and distinguishing them precisely matters less than treating the shared features: lash debris, lid margin colonization, and inflammation.

Posterior Blepharitis

Posterior blepharitis involves the meibomian glands — specialized sebaceous glands embedded in the tarsal plate of the eyelid, with their openings on the inner rim of the lid margin just behind the lash line. There are approximately 25–30 glands in the upper lid and 20–25 in the lower. Their function is to secrete meibum, the oily outer layer of the tear film that retards tear evaporation.

In posterior blepharitis, the meibomian gland orifices become plugged with thickened, keratinized secretions. The glands themselves eventually become distended and, with prolonged obstruction, undergo atrophy and fibrosis — a process called meibomian gland dropout, visible on infrared meibography imaging. The compromised lipid layer allows tears to evaporate rapidly, causing evaporative dry eye. The clinical signs of MGD include: capped or plugged meibomian orifices, turbid or toothpaste-like expressed secretions (healthy meibum should flow clear and liquid), frothy tears (lipid breakdown products foam at the tear meniscus), and telangiectatic (dilated) blood vessels crossing the lid margin.

Mixed Blepharitis

Many patients, particularly those who have had blepharitis for years, have features of both anterior and posterior disease. The bacterial and inflammatory mediators from anterior blepharitis migrate posteriorly and inflame meibomian gland orifices; conversely, the abnormal lipid environment from MGD alters the lid margin's bacterial microbiome, worsening anterior disease. Recognizing the mixed picture matters when planning treatment — these patients benefit from both lid scrubs targeting the anterior margin and heat/expression targeting the posterior glands.

Back to Table of Contents

The Demodex Connection

Demodex folliculorum and Demodex brevis are microscopic mites — eight-legged arachnids about 0.3–0.4 mm long — that live obligatorily in the hair follicles and sebaceous glands of humans. They are found throughout the body: face, scalp, chest, and eyelids. In low numbers they are considered normal commensals, generally harmless residents of the skin ecosystem. The trouble begins when their population grows too large.

On the eyelids, D. folliculorum prefers the lash follicles, while D. brevis favors the deeper meibomian and accessory sebaceous glands. In Demodex blepharitis, mite burdens are elevated (more than one to two mites per lash is considered abnormal in most clinical studies). The mites contribute to blepharitis through several mechanisms:

The hallmark clinical sign of Demodex blepharitis is cylindrical dandruff (CD) — translucent, whitish-grey, sleeve-like deposits wrapping around the base of individual eyelashes. These sleeves (composed of mite bodies, eggs, and debris) are distinct from the hard crusts of staphylococcal blepharitis and from the greasy flakes of seborrheic disease. Epilation of a lash followed by immediate microscopy can directly visualize the mites. Some clinicians use dermoscopy of the lid margin to detect mite movement without epilation.

In 2023, the FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) — the first prescription therapy specifically approved for Demodex blepharitis. Lotilaner is a benzoxazoline isoxazoline antiparasitic that works by blocking GABA-gated chloride channels in the mite's nervous system, causing paralysis and death. The approved regimen is one drop in each eye twice daily for six weeks. The pivotal trials (SATURN-1 and SATURN-2) showed significant reductions in both cylindrical dandruff and mite counts compared to vehicle, with collarette resolution in roughly half of patients at day 43.

For patients who cannot access or afford Xdemvy, tea tree oil (TTO)-based lid wipes remain a widely used, off-label alternative. Tea tree oil contains terpinen-4-ol, which has in vitro acaricidal activity against Demodex. Commercial products (Cliradex wipes, Ocusoft TTO wipes) use diluted concentrations safe for the periocular area. Pure tea tree oil must never be applied to the eyes — concentrations above 5% are irritating and potentially toxic to the corneal epithelium.

Back to Table of Contents

Meibomian Gland Dysfunction and Dry Eye

Posterior blepharitis — meibomian gland dysfunction (MGD) — is the most important cause of evaporative dry eye disease, which is itself the most common form of dry eye. Understanding this link explains why so many dry eye patients fail to improve with artificial tears alone: if the underlying problem is a deficient lipid layer from dysfunctional meibomian glands, replacing the aqueous tear component does not address the root cause.

The tear film has three main layers: an inner mucin layer (secreted by goblet cells on the conjunctiva, anchoring the tear to the eye surface), a middle aqueous layer (secreted by the lacrimal gland), and an outer lipid layer (meibum from the meibomian glands). The lipid layer acts as a hydrophobic seal that retards evaporation of the aqueous layer. When meibum quality degrades or quantity diminishes, the tear film evaporates too quickly — tear film breakup time (TBUT) shortens, leaving dry patches on the cornea between blinks. Patients experience burning, stinging, blurred vision that clears with blinking, and paradoxically, reflex tearing (the eye produces extra aqueous to compensate, but without adequate lipid coverage these reflex tears also evaporate rapidly).

The International Workshop on Meibomian Gland Dysfunction (2011, published as a supplement to Investigative Ophthalmology & Visual Science) established MGD as the leading cause of dry eye worldwide. Estimates suggest that evaporative dry eye accounts for approximately 30% of dry eye cases in Western populations and up to 86% in some Asian populations — with MGD driving the vast majority of evaporative cases.

The meibomian glands are not simply blocked; they undergo gradual structural loss. Meibography — infrared imaging of the lid to visualize gland architecture — shows that in established MGD, glands shorten from the tip (truncation), develop dropout areas (ghostly zones where functional gland tissue has been replaced by fibrous tissue), and eventually disappear. This gland dropout is largely irreversible with current therapies. Early treatment of MGD is therefore important not only to relieve symptoms but to prevent permanent gland loss.

The clinical implication for patients: if you have been told you have dry eyes and artificial tears are not helping, ask your eye doctor to look specifically at your meibomian glands. A quick "meibomian gland expression" — pressing on the lid margin to see what comes out — is informative in seconds. Clear, oily meibum flows easily in healthy glands. Toothpaste-like, cloudy, or absent secretions indicate MGD. Meibography is not universally available, but where it is, it can motivate patients to maintain lid hygiene by showing them the structural damage already present.

Back to Table of Contents

Seborrheic Dermatitis Association

Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition characterized by redness, scaling, and greasiness in areas rich in sebaceous glands: the scalp (classic dandruff), the nasolabial folds, the eyebrows, the glabella (between the brows), the central chest, and the external ear canals. It affects roughly 3–5% of the general population and up to 40% of people with HIV.

The pathophysiology of seborrheic dermatitis involves the interplay between sebum production, colonization by Malassezia yeast (particularly M. globosa and M. restricta), and an abnormal host immune response. Malassezia metabolizes sebum lipids and releases free fatty acids and other metabolites that trigger inflammation. The same dynamic plays out on the eyelid margin, where Malassezia colonization contributes to the greasy scaling of seborrheic anterior blepharitis and adds to the inflammatory milieu that worsens MGD.

The connection between scalp and eyelid disease is clinically useful. When a patient presents with seborrheic blepharitis, asking about dandruff, facial oiliness, and ear canal scaling costs nothing and often reveals an extensive seborrheic diathesis. Conversely, when a dermatologist treats a patient for severe scalp seborrheic dermatitis, asking about eye symptoms and referring to an ophthalmologist may uncover untreated blepharitis.

Treatment implications: medicated shampoos containing zinc pyrithione, selenium sulfide, or ketoconazole are effective for scalp seborrheic dermatitis. These can be gently lathered onto the closed eyelids and rinsed off as part of a shower routine — an approach endorsed in some clinical guidelines for seborrheic blepharitis specifically. Importantly, this is NOT the same as applying undiluted product to the open eye; careful technique is required, and patients should close their eyes firmly. For patients with prominent facial seborrheic dermatitis, topical antifungals (ketoconazole cream, ciclopirox cream) applied to the face also tend to reduce lid margin disease.

Topical calcineurin inhibitors (tacrolimus, pimecrolimus) — used in seborrheic dermatitis and atopic dermatitis — are sometimes used near the eyelids when standard treatments fail, though their use near the ocular surface requires caution and ophthalmologic guidance.

Back to Table of Contents

Symptoms and Diagnosis

Blepharitis produces a recognizable symptom cluster, though no single symptom is pathognomonic. Patients often describe a slow-onset, chronic picture that they have attributed to allergies, fatigue, or "just my eyes" for years.

Symptoms

Diagnosis

There is no single diagnostic test for blepharitis. Diagnosis is clinical, based on the history and slit-lamp examination. Key slit-lamp findings include:

Additional diagnostic tools: meibography (infrared imaging to assess gland dropout); eyelash epilation and microscopy for Demodex counting; lid margin eversion and biomicroscopy under higher magnification. Schirmer's test (tear production volume) is more useful for diagnosing aqueous deficiency dry eye than for blepharitis itself.

The differential diagnosis includes allergic or giant papillary conjunctivitis, contact dermatitis of the lid (from makeup, eye drops, or systemic medications), lid-margin tumors (especially sebaceous cell carcinoma masquerading as chronic unilateral blepharitis — always biopsy a chronic unilateral case unresponsive to treatment), and viral or bacterial conjunctivitis.

Back to Table of Contents

First-Line Treatment: Warm Compresses and Lid Hygiene

The cornerstone of blepharitis management is daily lid hygiene: a two-step routine of warm heat followed by mechanical cleaning. This works for both anterior and posterior disease — heat softens the gland secretions; scrubbing removes lash-base debris and bacteria. No prescription is needed, and this alone controls mild-to-moderate blepharitis in most patients. The catch: it must be done every day, indefinitely.

Step 1: Warm Compresses

The goal is to heat the eyelid surface to approximately 40°C (104°F) for five to ten minutes. This temperature melts the solid or semi-solid abnormal meibum that plugs the gland orifices, allowing it to flow out. The lid surface must reach and maintain this temperature — which is harder than it sounds, because the normal body temperature of the eyelid is about 34°C and a standard wet washcloth cools quickly.

Options by effectiveness:

Apply the compress to both closed eyes simultaneously. Some patients watch TV or listen to podcasts during the five minutes to make the routine easier to sustain.

Step 2: Lid Massage

Immediately after the compress, while the meibum is still warm and liquid, gentle massage along the lid margin (rolling a clean fingertip along the base of the lashes, pressing inward toward the eye surface) helps express the softened secretions from the glands. This is the mechanical equivalent of what a clinician does during an in-office meibomian gland expression. Some patients find massage uncomfortable initially; consistent daily practice reduces sensitivity.

Step 3: Lid Scrubs

After heat and massage, clean the lash base and lid margin to remove crusts, scales, Demodex debris, and excess bacteria. Apply the cleaning agent to a clean fingertip, cotton swab, or dedicated applicator pad and scrub the lash base with a back-and-forth motion for 30–60 seconds per lid. Rinse.

Products:

Frequency: twice daily during acute flares, once daily for maintenance. The morning session is particularly important — clearing overnight crusts before activity reduces daytime symptoms significantly. Some patients manage on every-other-day maintenance once symptoms are stable; most do best with daily hygiene.

Emphasize to patients: the goal is not to achieve a "cure" that then needs no further treatment. Blepharitis is a structural and microbiome problem that recurs when hygiene lapses — exactly like dental plaque. Explaining this analogy (brushing teeth for eye health) is one of the most effective ways to motivate long-term adherence.

Back to Table of Contents

The Baby Shampoo Myth

For decades, ophthalmologists worldwide routinely recommended diluted baby shampoo as the lid cleanser of choice for blepharitis. The logic was appealing: baby shampoo is cheap, universally available, gentle enough for infants, and advertised as "tear-free." Patients were told to dilute it 1:1 or 1:10 with water and scrub their lid margins with a washcloth or cotton swab.

The reality is more complicated, and the evidence no longer supports baby shampoo as a preferred lid cleanser.

First, the "tear-free" label refers to the avoidance of stinging on the conjunctiva, not safety for the eyelid margin or ocular surface cells. Shampoos achieve their tear-free property through pH adjustment and surfactant selection — but those same properties make them potentially harmful when applied repeatedly to the lid margin, which is a delicate mucocutaneous junction in direct contact with the ocular surface.

A study by Sung et al. published in Optometry and Vision Science (2012) tested baby shampoo on human corneal epithelial cells in culture and found significant cytotoxicity. The shampoo caused cell death at concentrations used in typical clinical dilutions. Importantly, commercial lid hygiene products (Ocusoft Lid Scrub) showed significantly less cytotoxicity in the same assay, challenging the assumption that baby shampoo's "gentle" reputation translates to safety on the ocular surface.

Second, baby shampoo has a pH of approximately 7.0, which is within the range of detergent products designed for skin. The tear film pH is approximately 7.4, and the ocular surface epithelium is exquisitely pH-sensitive. Repeated application of a mildly acidic surfactant to the lid margin may disrupt the epithelial tight junctions that protect the ocular surface from microbial ingress and mechanical damage.

Third, baby shampoo has no specific activity against Demodex mites, biofilm-embedded bacteria, or abnormal meibum. Commercial products with targeted active ingredients — terpinen-4-ol for Demodex, hypochlorous acid for bacteria, phospholipid surfactants that mimic meibum — address the specific pathophysiology of blepharitis more rationally.

The bottom line: if you or your patients have been using baby shampoo for years and it seems to help, the benefit is probably mechanical — the act of scrubbing, not the shampoo itself. Switching to a dedicated lid hygiene product (especially one containing tea tree oil or HOCL) is likely to improve efficacy and reduce ocular surface irritation. This is one case where the traditional recommendation has been overtaken by the evidence. The baby shampoo era of blepharitis treatment is coming to an end.

Back to Table of Contents

Medications: Azithromycin, Doxycycline, Topical Steroids

When daily lid hygiene alone is insufficient to control blepharitis — either because inflammation is moderate-to-severe, because the patient has posterior MGD requiring normalization of meibum lipid quality, or because Demodex or bacterial loads are high — medications are added.

Topical Azithromycin (AzaSite 1%)

Azithromycin in the DuraSite polymer vehicle was FDA-approved for bacterial conjunctivitis, but extensive off-label use and clinical trial evidence support its application to the eyelid margin for blepharitis. Azithromycin is a macrolide antibiotic with substantial anti-inflammatory properties independent of its antibacterial activity — it inhibits production of pro-inflammatory cytokines (IL-1β, TNF-α) and matrix metalloproteinases (particularly MMP-9), reduces biofilm formation, and modulates the gland-clogging lipid composition of meibum.

A pivotal randomized controlled trial by Luchs (2010, Clinical Ophthalmology, PMID 20182181) demonstrated that twice-daily topical azithromycin applied to the lid margin for one month significantly reduced lid margin signs (telangiectases, orifice plugging), improved meibum quality on expression, and reduced dry eye symptoms compared to placebo. The formulation is applied with a clean fingertip directly to the lid margins — not instilled into the eye — and works locally on the glands.

Topical azithromycin is convenient (once or twice daily), avoids systemic exposure and GI side effects, and has a favorable safety profile. Its one disadvantage is cost — generic AzaSite may not be covered by all insurance plans, and the branded product can be expensive.

Oral Doxycycline

Oral doxycycline is a tetracycline antibiotic that, at the doses used for blepharitis, works primarily through anti-inflammatory and lipid-modifying mechanisms rather than bacterial killing. This matters for two reasons: (1) it explains why doxycycline works for MGD even when bacteria are not the primary driver; and (2) it has led to the development of sub-antimicrobial-dose doxycycline (20 mg twice daily, as in Periostat) that achieves the anti-inflammatory effect while minimizing antibiotic selection pressure.

Standard dosing for blepharitis: 50–100 mg once or twice daily for 6–12 weeks. Doxycycline inhibits matrix metalloproteinases (MMP-8, MMP-9) that degrade the meibomian gland ductal walls, suppresses the phospholipase enzymes that S. aureus and Bacillus oleronius use to generate toxic free fatty acids from meibum lipids, and shifts the meibum lipid composition toward healthier, less viscous fatty acid profiles.

Practical cautions: doxycycline causes photosensitivity — patients must use sunscreen. It causes esophageal ulceration if swallowed lying down — always taken upright with a full glass of water. It should not be used in pregnant women (dental/bone effects) or children under 8. GI upset (nausea, reflux) is common; taking with food (but not dairy) reduces this. It is contraindicated with most antacids containing divalent cations (calcium, magnesium) which chelate doxycycline and prevent absorption.

Topical Corticosteroids

Short courses of topical corticosteroid eye drops or ointments (prednisolone acetate, fluorometholone, loteprednol etabonate) are useful for rapidly controlling acute inflammatory flares of blepharitis that are causing significant discomfort or threatening ocular surface integrity. They work quickly — often providing relief within 48–72 hours.

Long-term use of topical corticosteroids near the eye carries well-established risks: elevated intraocular pressure (IOP) — a risk factor for glaucoma in steroid-responders; posterior subcapsular cataract formation with prolonged use; and susceptibility to herpetic keratitis if HSV is present on the cornea. For these reasons, topical steroids are used for short courses only (typically one to two weeks) and are not appropriate as long-term maintenance therapy for blepharitis. Loteprednol etabonate has a lower IOP-raising propensity than prednisolone and is preferred by some clinicians for lid margin inflammation when a steroid is needed.

Lotilaner 0.25% (Xdemvy)

For Demodex-specific disease, FDA-approved lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals) represents a genuine advance. The SATURN-1 (NCT04730804) and SATURN-2 (NCT04730817) pivotal trials enrolled a combined 833 patients with Demodex blepharitis diagnosed by collarette count. Twice-daily dosing for 6 weeks produced significantly greater reduction in collarettes (primary endpoint) and improvement in eyelid erythema and itching versus vehicle. The drug was well tolerated; the most common adverse event was instillation-site stinging (8%), which resolved promptly. Importantly, responders at 6 weeks maintained improvement at the 6-month follow-up without continued use, though repeat treatment is available for relapse.

Back to Table of Contents

Intense Pulsed Light (IPL) for MGD-Associated Blepharitis

Intense pulsed light therapy is a broad-spectrum pulsed light technology (wavelengths typically 500–1200 nm, filtered to exclude UV) originally developed for dermatologic applications: photoaging, rosacea, telangectases, acne, and hair removal. Its application to blepharitis arose serendipitously: clinicians treating rosacea patients with IPL on the face noticed that their dry eye and blepharitis symptoms improved, even though the IPL was not applied near the eyes per se. Investigation revealed that IPL applied to the cheekbones and lower eyelid skin had meaningful effects on meibomian gland function.

Mechanisms

IPL for MGD is thought to work through multiple mechanisms:

Clinical Protocol and Evidence

The standard IPL protocol for MGD typically involves four monthly treatment sessions. Each session applies pulsed light to the cheekbones, lower lids, and sometimes upper lids. Immediately after IPL, the clinician performs manual meibomian gland expression (forceps or paddle) to expel the now-liquefied secretions — this combination appears significantly more effective than either intervention alone.

Multiple randomized controlled trials now support IPL + meibomian gland expression for MGD-associated dry eye. A 2020 RCT by Rong et al. (Journal of Ophthalmology) showed significantly improved TBUT, meibomian gland score, and dry eye questionnaire scores at 3 months compared to sham treatment. A 2019 RCT by Jiang et al. (BMC Ophthalmology) found IPL produced superior results to meibomian gland expression alone at 3 months. Systematic reviews and meta-analyses confirm the signal, though study heterogeneity (different devices, fluences, filters, patient populations) makes pooled analyses challenging.

Patient Selection and Safety

IPL is appropriate for patients with moderate-to-severe MGD-associated blepharitis who have not responded adequately to lid hygiene, oral doxycycline, and in-office gland expression. It is particularly effective in patients with visible telangiectases on the lid margins and those with concomitant rosacea.

Key contraindications and cautions:

IPL sessions for MGD are typically not covered by vision or medical insurance in the United States, as the technology is classified as cosmetic in many plans. Out-of-pocket cost ranges from $300–$600 per session. For patients with severe, treatment-resistant MGD, the functional improvement in dry eye symptoms frequently makes the cost worthwhile.

Back to Table of Contents

Key Research Papers

  1. Nichols KK et al. — International Workshop on Meibomian Gland Dysfunction (2011): the foundational multi-author consensus report establishing MGD as the leading cause of evaporative dry eye. Search on PubMed
  2. Cheng AM, Sheha H, Tseng SC — Demodex blepharitis prevalence and the clinical significance of mite burden: Search on PubMed
  3. Gaddie IB et al. — Lotilaner (Xdemvy) pivotal SATURN trials for Demodex blepharitis (2023): Search on PubMed
  4. Sung J et al. — Baby shampoo cytotoxicity on ocular surface epithelial cells (Optometry and Vision Science, 2012): Search on PubMed
  5. Luchs J — Azithromycin in DuraSite (AzaSite) for treatment of blepharitis (Clinical Ophthalmology, 2010; PMID 20182181): Search on PubMed
  6. Doxycycline for meibomian gland dysfunction and blepharitis — anti-inflammatory mechanism and clinical outcomes: Search on PubMed
  7. Intense pulsed light (IPL) for MGD — randomized controlled trials: Search on PubMed
  8. MGD prevalence as the leading cause of evaporative dry eye: Search on PubMed
  9. Lid scrub and lid hygiene product efficacy in blepharitis: Search on PubMed
  10. Tea tree oil terpinen-4-ol against Demodex eyelid mites: Search on PubMed
  11. Rosacea and ocular blepharitis — shared pathophysiology and co-management: Search on PubMed
  12. Warm compresses and heat therapy for meibomian gland dysfunction: Search on PubMed

Back to Table of Contents

Connections

Back to Table of Contents